Clicky

Vaxart, Inc.(VXRT)

Description: Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.


Keywords: Medicine Cancer Vaccines Influenza Vaccination Hepatitis B Coronavirus HPV Papillomavirus Vaccine Preventable Diseases Human Papilloma Virus Human Papillomavirus Infection Seasonal Influenza

Home Page: vaxart.com

VXRT Technical Analysis

170 Harbor Way
South San Francisco, CA 94080
United States
Phone: 650 550 3500


Officers

Name Title
Mr. Cezar Andrei Floroiu M.B.A. CEO, Pres & Director
Dr. Sean N. Tucker Sr. VP & Chief Scientific Officer
Dr. James F. Cummings M.D. Chief Medical Officer
Mr. Fuad Ahmad Interim CFO and Principal Financial & Accounting Officer
Dr. Raymond D. Stapleton Jr., Ph.D. Chief Technology Officer
Mr. Edward B. Berg Sr. VP & Gen. Counsel
Ms. Shaily Jaini Garg Sr. VP of Clinical Devel. & Project Management
Mr. Brant Biehn Sr. VP of Bus. Operations
Dr. Rajesh Kapoor Ph.D. Sr. VP of Quality
Mr. John M. Harland M.B.A., CPA Consultant

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 42.735
Trailing PE: 0
Price-to-Book MRQ: 1.1053
Price-to-Sales TTM: 916.2665
IPO Date: 2018-02-12
Fiscal Year End: December
Full Time Employees: 110
Back to stocks